MARKET

RDUS

RDUS

Radius Health
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.11
-0.05
-0.38%
Closed 16:46 03/30 EDT
OPEN
13.01
PREV CLOSE
13.16
HIGH
13.60
LOW
12.82
VOLUME
392.51K
TURNOVER
--
52 WEEK HIGH
29.97
52 WEEK LOW
10.32
MARKET CAP
605.91M
P/E (TTM)
-4.5334
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of RDUS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average RDUS stock price target is 31.17 with a high estimate of 39.00 and a low estimate of 23.00.

EPS

RDUS News

More
  • Radius Health (RDUS) Down 33.3% Since Last Earnings Report: Can It Rebound?
  • Zacks · 2d ago
  • The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
  • Benzinga · 03/17 15:38
  • The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
  • Benzinga · 03/13 11:52
  • Radius Health: It Is Better To Wait And See
  • Seeking Alpha - Article · 03/11 17:40

Industry

Biotechnology & Medical Research
+4.00%
Pharmaceuticals & Medical Research
+4.75%

Hot Stocks

Symbol
Price
%Change

About RDUS

Radius Health, Inc. is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company's lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Company’s clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its RAD140 is a non-steroidal, selective androgen receptor modulator (SARM). RAD140 is under development for potential use in hormone receptor positive breast cancer.
More

Webull offers kinds of Radius Health Inc stock information, including NASDAQ:RDUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RDUS stock news, and many more online research tools to help you make informed decisions.